Immunome, Inc.
IMNM
$15.67
-$0.82-4.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -212.39M | -205.11M | -292.96M | -305.35M | -262.59M |
| Total Depreciation and Amortization | 2.61M | 2.57M | 2.10M | 1.76M | 1.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 52.35M | 56.50M | 165.19M | 215.73M | 207.02M |
| Change in Net Operating Assets | -21.26M | -6.64M | 14.87M | 1.66M | -6.42M |
| Cash from Operations | -178.68M | -152.68M | -110.79M | -86.19M | -60.64M |
| Capital Expenditure | -53.57M | -55.01M | -53.51M | -52.48M | -4.89M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 9.28M | 9.28M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.34M | 12.27M | -31.56M | -81.62M | -153.34M |
| Cash from Investing | -25.23M | -42.74M | -85.06M | -124.82M | -148.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 193.92M | 194.87M | 255.76M | 235.64M | 235.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.36M | -11.56M | -15.23M | 40.30M | 101.38M |
| Cash from Financing | 182.56M | 183.31M | 240.53M | 275.94M | 336.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.35M | -12.11M | 44.67M | 64.93M | 126.92M |